|Bid||86.19 x 1000|
|Ask||87.20 x 1000|
|Day's Range||86.25 - 87.20|
|52 Week Range||66.10 - 87.25|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||24.32|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||2.20 (2.53%)|
|1y Target Est||95.60|
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
On CNBC's "Trading Nation," Mark Newton of Newton Advisors recommended Twitter Inc (NYSE: TWTR ) and Merck & Co., Inc. (NYSE: MRK ) as stocks to buy in the current market environment. He said ...
Pooled Overall Survival Data from Three Trials with KEYTRUDA® Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer Whose Tumors Do
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
"If the products that the (FDA) is approving aren't standing the test of time, are they going to become more tentative with drug approvals? (Cell and gene therapies) may bring that issue to the forefront," one regulatory expert said.
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women Who Responded to Platinum-Base
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
With the change of leadership for GSK's pharmaceutical business, the Triangle won't necessarily be losing its GSK leader.
Does the August share price for Merck & Co., Inc. (NYSE:MRK) reflect what it's really worth? Today, we will estimate...